Towards Tomorrow: Transforming Sarcoma Care HTA in Bulgaria

Slavchev G¹, Seitaridou Y¹, Yankova I^{1,} Georgieva M¹, Dacheva A¹, Vitanova L², Djambazov S¹ ¹HTA, Ltd

²Association "Together Against Sarcoma"



HSD90

INTRODUCTION

Sarcomas are a heterogeneous group of rare malignant tumors of mesenchymal origin, classified mainly into bone sarcomas and soft tissue sarcomas. Sarcomas represent over 20% of solid cancers in children but less

than 1% in adults.⁽¹⁾ Comparing sarcoma care practices in the United States, United Kingdom, Europe, and

Bulgaria, an in-depth review of the status and challenges of sarcoma care is presented.

METHODS

M . + . .

Qualitative data on sarcoma treatment practices, patient outcomes, and healthcare infrastructure in Bulgaria was collected in collaboration with the Bulgarian non-governmental organization "Together against Sarcoma" and clinical experts.



OBJECTIVE

The goal of the project is to perform gap analysis in sarcoma patient treatment
and develop and propose
strategies for improvement
in Bulgaria.



Delays in clinical decision making

Compromised quality of life



The lack of specialized sarcoma centers with multidisciplinary teams impedes timely and effective care, compromising patient outcomes and quality of life. An exemplary patient pathway, multidisciplinary team structure, and criteria for dedicated centers offer a framework to address these gaps. Implementing these measures is crucial to improve sarcoma care quality, patient survival rates and well-being in

Bulgaria.

REFERENCES

1. Yang J, Ren Z, Du X, Hao M, Zhou W. The role of mesenchymal stem/progenitor cells in sarcoma: update and dispute. Stem Cell Investig. 2014;1:18. doi:10.3978/J.ISSN.2306-9759.2014.10.01